Publicacións nas que colabora con José Ramón Arribas López (28)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort

    Clinical Microbiology and Infection, Vol. 27, Núm. 11, pp. 1678-1684

  3. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 244-252

2020

  1. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

    Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536

  2. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  3. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  4. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2018

  1. Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 36, Núm. 5, pp. 268-276

  2. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  3. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

  2. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2015

  1. Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: A randomized clinical trial

    Clinical Infectious Diseases, Vol. 60, Núm. 5, pp. 811-820

  2. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2014

  1. Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2014)

    Enfermedades Infecciosas y Microbiologia Clinica Monografias, Vol. 32, Núm. 7, pp. 446e1-446e42